Sugi Predict

Sugi Predict / Compounds / SCHEMBL2657735

SCHEMBL2657735

SCHEMBL2657735

CC(C)(C)c1ccc(C(Br)C(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 2/20 0.47
▸ CES2 O00748 1/20 0.47
▸ CES1 P23141 1/20 0.47
▸ SRD5A2 P31213 1/20 0.46
▸ AKR1C3 P42330 1/20 0.45
▸ AKR1C2 P52895 1/20 0.45
▸ KIF11 P52732 1/20 0.44
▸ MAPT P10636 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ FFAR1 O14842 1/20 0.43
▸ HDAC1 Q13547 1/20 0.42
▸ EPHX1 P07099 5/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ RARB P10826 1/20 0.42
▸ RARG P13631 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TNF P01375 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7448575 0.80 GSK3B (0.53) CES2CES1SRD5A2AKR1C3AKR1C2
SCHEMBL7372260 0.79 MAPT (0.44) NR1H4SRD5A2MAPTTDP1HDAC1
SCHEMBL3591632 0.79 NR1H4 (0.50) NR1H4SRD5A2AKR1C3AKR1C2KIF11
SCHEMBL6951155 0.79 SRC (0.54) NR1H4SRD5A2AKR1C3AKR1C2KIF11
SCHEMBL1716479 0.78 NR1H4 (0.71) NR1H4SRD5A2AKR1C3AKR1C2FFAR1
SCHEMBL21269797 0.78 SRC (0.52) NR1H4SRD5A2AKR1C3AKR1C2KIF11
SCHEMBL21269219 0.78 SRC (0.52) NR1H4SRD5A2AKR1C3AKR1C2KIF11
SCHEMBL21268997 0.78 SRC (0.52) NR1H4SRD5A2AKR1C3AKR1C2KIF11
SCHEMBL11238948 0.78 LMNA (0.56) NR1H4CES2CES1SRD5A2AKR1C3
Iodide SCHEMBL31045512 0.78 NR1H4 (0.53) NR1H4SRD5A2AKR1C3AKR1C2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 — — US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 — — EP disclosed
CN-107669669-A novel glucagon receptor antagonist 症变治疗公司 2018-02-09 — — CN disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
CN-101610995-B Glucagon receptor antagonists 症变治疗公司 2017-08-08 — — CN disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 — — CN disclosed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 NR1H4 99/4885CES2 4048/4885CES1 1202/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 NR1H4 84/4885CES2 3982/4885CES1 1287/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 NR1H4 99/4885CES2 4023/4885CES1 1170/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 NR1H4 99/4885CES2 4023/4885CES1 1170/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 NR1H4 99/4885CES2 4023/4885CES1 1170/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 NR1H4 84/4885CES2 3998/4885CES1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.